Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mycophenolic acid
Drug ID BADD_D01508
Description Mycophenolic acid is an an immunosuppresant drug and potent anti-proliferative, and can be used in place of the older anti-proliferative azathioprine. It is usually used as part of triple therapy including a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. It is also useful in research for the selection of animal cells that express the E. coli gene coding for XGPRT (xanthine guanine phosphoribosyltransferase).
Indications and Usage For the prophylaxis of organ rejection in patients receiving allogeneic renal transplants, administered in combination with cyclosporine and corticosteroids.
Marketing Status Prescription; Discontinued
ATC Code L04AA06
DrugBank ID DB01024
KEGG ID D05096
MeSH ID D009173
PubChem ID 446541
TTD Drug ID D04FBR
NDC Product Code 70518-3218; 60429-016; 72322-1049; 68084-918; 0904-6785; 60505-2965; 68254-5001; 68254-5002; 0078-0385; 70748-218; 70518-3255; 68084-907; 0904-6786; 24979-160; 50268-559; 51187-0004; 0378-4201; 60505-2966; 67877-426; 52076-6215; 0378-4202; 16729-261; 67877-427; 16729-189; 72322-1048; 70436-172; 60429-017; 24979-161; 20076-0405; 0078-0386; 70436-173; 57885-0009; 65727-011; 70748-217
Synonyms Mycophenolic Acid | Mycophenolate Mofetil | Mofetil, Mycophenolate | Mycophenolic Acid Morpholinoethyl Ester | Cellcept | Mycophenolate Sodium | Sodium Mycophenolate | Mycophenolate, Sodium | Myfortic | Mycophenolate Mofetil Hydrochloride | Mofetil Hydrochloride, Mycophenolate | RS 61443 | RS-61443 | RS61443
Chemical Information
Molecular Formula C17H20O6
CAS Registry Number 24280-93-1
SMILES CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Local swelling08.01.03.0130.001737%Not Available
Localised infection11.01.08.0060.001737%Not Available
Loss of consciousness17.02.04.0040.003474%Not Available
Lower respiratory tract infection11.01.09.002; 22.07.01.0020.001158%Not Available
Lung disorder22.02.07.0010.003474%Not Available
Lymphadenopathy01.09.01.002--Not Available
Lymphoma01.12.01.001; 16.20.01.001--Not Available
Lymphopenia01.02.02.002--Not Available
Malaise08.01.01.0030.011580%
Malignant melanoma23.08.01.001; 16.03.01.001--Not Available
Melaena24.07.02.013; 07.12.02.004--Not Available
Memory impairment17.03.02.003; 19.20.01.0030.001158%
Meningitis17.06.03.001; 11.01.03.001--
Mental disability26.01.01.001--Not Available
Micturition urgency20.02.02.006--
Mood swings19.04.03.001--Not Available
Mouth ulceration07.05.06.004--Not Available
Multiple congenital abnormalities03.02.01.003--Not Available
Muscle spasms15.05.03.004--
Muscle twitching15.05.03.005--Not Available
Muscular weakness17.05.03.005; 15.05.06.001--
Myalgia15.05.02.001--
Mydriasis17.02.11.003; 06.05.03.004--Not Available
Myocardial infarction24.04.04.009; 02.02.02.007--
Nasal congestion22.04.04.001--
Nasal dryness22.04.03.002--Not Available
Nasopharyngitis11.01.13.002; 22.07.03.0020.002895%Not Available
Nausea07.01.07.0010.011580%
Neck pain15.03.04.009--
Neonatal disorder18.04.01.001--Not Available
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 17 Pages